Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.35 |
| ▸ | ARG2 | P78540 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22600212 | 0.84 | ACHE (0.35) | ARG1ARG2CHRM4NOS3NOS1 | |
| SCHEMBL19788224 | 0.80 | ARG1 (0.32) | ARG1ARG2 | |
| SCHEMBL14102866 | 0.80 | HTT (0.33) | — | |
| SCHEMBL20317403 | 0.79 | CACNA1I (0.40) | OPRL1 | |
| SCHEMBL25877203 | 0.79 | ARG1 (0.41) | ARG1ARG2CHRM4NOS3NOS1 | |
| SCHEMBL23105099 | 0.78 | ARG1 (0.40) | ARG1ARG2CHRM4NOS3NOS1 | |
| SCHEMBL25915237 | 0.78 | HTT (0.32) | — | |
| SCHEMBL25848264 | 0.76 | — | — | |
| SCHEMBL23594363 | 0.76 | ATM (0.31) | — | |
| SCHEMBL26805516 | 0.76 | HRH3 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339572-A1 | NOVEL SELECTIVE CDK4/6 INHIBITOR AND PREPARATION THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339572-A1 | NOVEL SELECTIVE CDK4/6 INHIBITOR AND PREPARATION THEREOF | CDK4, CDK6, CCNI | ARG1 4008/4885ARG2 4629/4885CHRM4 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.